Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company specializing in in-licensing, developing, and commercializing treatments for rare and difficult-to-treat diseases. Its core products include FIRDAPSE® for Lambert-Eaton myasthenic syndrome, FYCOMPA® for epilepsy, and AGAMREE® for Duchenne muscular dystrophy. Catalyst targets niche patient populations through specialized sales forces, personalized patient support programs, and partnerships, focusing on orphan drug markets with strong intellectual property protections.
This description was generated via AI from an annual report. Updated about 1 year ago.